European Journal of Biomedical and Pharmaceutical Sciences

CLINICAL PRACTICE PERSPECTIVES ON MANAGING PATIENT ON ANTICOAGULANT/ ANTIPLATELET THERAPY DURING DENTAL PROCEDURES: AN UPDATED NARRATIVE REVIEW

Dr. Sweta Singh, *Dr. Shailendra Kumar, DM, Dr. Yudhyavir Singh, MD, Dr. Gaurav Singh Tomar, DM

ABSTRACT

Anticoagulant and antiplatelet agents are prescribed for individuals who are at high risk for or who have had thromboembolic events (e.g., blood clots). These include patients who have experienced deep-vein thrombosis (DVT) or pulmonary embolism (PE) or who have nonvalvular atrial fibrillation (NVAF), a cardiac arrhythmia that predisposes patients to clot formation. Anticoagulants include the vitamin K antagonist warfarin (Coumadin®) and the newer direct oral agents, including the direct thrombin inhibitor dabigatran (Pradaxa®) and the factor Xa inhibitors apixaban (Eliquis®), rivaroxaban (Xarelto®), and edoxaban (Savaysa® [Lixiana® in the European Union, Japan, and others]).[1-6] Antiplatelet agents include clopidogrel (Plavix®), ticlopidine (Ticlid®), prasugrel (Effient®), ticagrelor (Brilinta®), and/or aspirin[7] (Table 1). Adverse effects associated with these drugs can include prolonged bleeding or bruising.

Keywords: .